Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience

Aamir Jalal Al-Mosawi^{1,2*}

¹Advisor in Pediatrics and Pediatric Psychiatry Children Teaching Hospital of Baghdad Medical City

²Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad, Iraq

***Corresponding Author:** Aamir Jalal Al-Mosawi, Head, Iraq Headquarter of Copernicus Scientists International Panel Baghdad, Iraq

Abstract

Background: Autistic disorders have become increasingly known as pervasive developmental disorders since the 1980s. They have been recently called autism spectrum disorder mostly by the American Psychiatric Association. They include five chronic disorders marked by early impairment in socialization, communication, and behavior.

There is no curative therapy or therapies for autistic disorders, and they continue to be regarded as life long disorders. The aim of this paper is to describe our extensive experiences with treatment of autistic disorders with emphasis on the possibility of curing these disorders with a new therapeutic approach. Marked improvement or disappearance of autistic features in these disorders has not been reported with any therapy before.

Materials and methods: During the period from December, 2017 to November, 2019, 116 patients with various autistic disorders were observed at the pediatric psychiatry clinic of the Teaching Hospital of Baghdad Medical City. 84 (72.4%) patients were males and 32 (28.6%) females patients were females. The patients' ages ranged from two years to 16 years. The patients were from several provinces in Iraq including Baghdad, Saladdin, Najaf, Wassit, Kerbala, and Erbil in the North of Iraq).

The patients were reported previously in several publications [1, 7, 9, 10, 11]. All the patients had very poor speech development except the patients with Asperger syndrome. Most of the patients with a diagnosis other than Asperger syndrome were not saying any word and few patients were saying few words.

Most patients were treated with a new therapeutic approach which included injectable cerebrolysin as the main therapeutic component. Marked improvement or disappearance of autistic features in these disorders has not been reported with any therapy before.

The patients were treated with a new approach which aimed at improving the cardinal features of autistic disorders which include impairment of social interaction which is mostly manifested by poor responsiveness to their name, and infrequent engagement with others manifested by poor eye contact and infrequently looking to faces.

It was not possible to follow all the patients regularly nor was it possible to document details of the treatment and responses of all patients.

Results: Almost all the patients treated with the new therapeutic approach experienced some improvement and lessening of the autistic features during the follow-up period. Treatment was also associated with initiation of speech and improvement of repetitive behaviors. It was possible to document complete disappearance of the main autistic features in twenty patients.

It seems that the patients who achieved complete disappearance of the main autistic features will need an intensive learning especially of speech to abolish the effect of the time when they

were under the effect of autistic behavior, and to push them toward a possible cure of their illness.

Conclusion: In this paper, we have demonstrated the possibility of cure of autistic disorders including autism and Asperger syndrome with use of individualized courses of intramuscular cerebrolysin as the main therapy for the main autistic features (Impaired social interaction and communication dominated by the lack of response to their name and poor eye contact).

Understanding, a cure of autism will not immediately abolish the cumulative effect of the condition on learning, behavior, and speech development before cure.

Key words: Autism, Asperger syndrome, cerebrolysin, cure.

Introduction

Autistic disorders have become increasingly known as pervasive developmental disorders since the 1980s. They include five chronic disorders marked by early impairment in socialization, communication, and behavior [1, 2, 3, 4]. These disorders were first recognized by Grunya Efimovna Sukhareva in 1925, a Soviet pediatric psychiatrist who called these disorders autistic psychopathy [2, 5]. In general, most of manifestations of pervasive developmental disorders result from impairments in social interaction and communication and behavioral problems [1-6].

General manifestations of pervasive developmental disorders include [1, 2, 3]:

Impaired social interaction marked by lack of eye contact, lack of facial

responses and not responding to own name appropriately.

Difficulties in using and understanding language.

Unusual patterns of playing with toys and other objects that can be marked

by restricted interests.

Repetitive body movements or behavior patterns including hand flapping, hair twirling, foot tapping, spinning, or other complex movements.

The American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, 1994) divided pervasive developmental disorders five subgroups [1-3]:

Autistic disorder which is also called classical autism was first described by Leo Kanner in 1943[3, 6].

Asperger syndrome was first described by Grunya Efimovna Sukhareva, and later by Hans Asperger in 1944[3, 6].

The autistic psychopathies described in 1925 by Grunya Efimovna

Sukhareva and Hans Asperger were similar and characterized by the absence of significant impairment in language development and cognitive function [3, 6].

Lorna Wing was probably the first to use the term Asperger syndrome in the English-speaking medical community in her 1981 publication of a series of case studies of children showing similar symptoms [3, 6].

Uta Frith translated Asperger's paper to English in 1991, and published it as a book with Cambridge University Press [3, 6].

Asperger syndrome has become a standard diagnosis in 1992, when it was included in the tenth edition of the World Health Organization's diagnostic manual, International Classification of Diseases (ICD-10); in 1994, it was added to the fourth edition of the American Psychiatric Association's diagnostic reference, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [3, 6].

The World Health Organization (WHO) defined Asperger syndrome as one of the pervasive developmental disorders or autism spectrum disorders which are a variety of psychiatric conditions that are characterized by impairment of social interaction and non verbal communication, and by restricted and repetitive interests and behavior[3,6].

Rett disorder was most probably first described in German language in 1966 by Andreas Rett, a pediatrician in Vienna. Bengt Hagberg, a Swedish pediatrician, published an English article in 1983 and named the condition after Rett [3, 6, 7].

Childhood disintegrative disorder (Heller syndrome) is a rare heterogeneous clinical syndrome that is distinctive from

autism and Asperger syndrome. It is characterized by a significant developmental regression resulting in deterioration in behavioral and adaptive functioning including self-help skills with loss of language and social skills after a period of normal development for at least two years [3, 6, 8, 9]. The condition was first reported in 1908 by Theodor Heller in his paper "Über Dementia Infantilis". He called the condition "Dementia infantilis" [3, 6, 8, 9].

Pervasive developmental disorder not otherwise specified (Atypical autism).

This type reflects the marked variability of these disorders. It may include disorders with well defined clinical features such as regressive autism and autism with significant mental retardation which seems to be also classifiable under idiopathic mental retardation with significant autistic features [1, 2, 3].

Regressive autism is just like Heller syndrome, it is associated with initial normal development followed by loss of the previously acquired skills of socializing, communication, and language skills. However, regressive autism is not associated with features of dementia or significant mental retardation [4, 6].

PERVASIVE DEVELOPMENTAL DISORDERS HAS RECENTLY BEEN CALLED AUTISM SPECTRUM DISORDER MOSTLY BY THE AMERICAN PSYCHIATRIC ASSOCIATION, AND THE TERM PERVASIVE DEVELOPMENTAL DISORDERS HAS BEEN USED WITH THE TERM AUTISM SPECTRUM DISORDER INTERCHANGEABLY [2,3].

Patients and Methods

During the period from December, 2017 to November, 2019, 116 patients with various autistic disorders were observed at the pediatric psychiatry clinic of the Teaching Hospital of Baghdad Medical City. 84 (72.4%) patients were males and 32 (28.6%) females patients were females. The patients' ages ranged from two years to 16 years. The patients were from several provinces in Iraq including Baghdad, Najaf, Wassit, Kerbala, and Erbil in the North of Iraq). The patients were reported previously in several publications [1, 7, 9, 10, 11]. All the patients had very poor speech development except the patients

with Asperger syndrome. Most of the patients with a diagnosis other than Asperger syndrome were not saying any word and few patients were saying few words.

Most patients were treated with a new therapeutic approach which included injectable cerebrolysin as the main therapeutic component. Marked improvement or disappearance of autistic features in these disorders has not been reported with any therapy before.

The new approach aimed at improving the cardinal features of autistic disorders which include impairment of social interaction which is mostly manifested by poor responsiveness to their name, and infrequent engagement with others manifested by poor eye contact and infrequently looking to faces.

Most patients also required neuroleptics to control hyperactivity and other abnormal behaviors. Trifluoperazine and prochlorperazine were used as frequently. Risperidone was also used in some patients when necessary. Some patients also received citicoline as an adjunctive therapy to improve speech development.

It was expected that improving social interaction will contribute to improving other features especially verbal communication and speech.

Courses of intramuscular cerebrolysin were given in individualized regimen depending on the age and severity of the illness, and with aim of improving social interactions including response to name, looking at faces, and eye contact.

It was not possible to follow all the patients regularly nor was it possible to document details of the treatment and responses of all patients.

The protocol for this research was approved by the scientific committee of Iraq headquarter of Copernicus Scientists International Panel and conforms to the provisions laid out in the Declaration of Helsinki (as revised in Edinburgh 2000):

www.wma.net/e/policy/b3.htm.

In the first nineteen patients observed initially during the period from December, 2017 to January, 2019 [10], only eight patients (Seven males and one

Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience

female) were treated with the new therapeutic approach. The patients' ages ranged from 3 to 8 years. Seven patients had a diagnosis of autism and one patient had a diagnosis of Asperger syndrome (Patient-5). Risperidone was used in one patient.

Table-1 shows the courses of therapy received by the eight treated patients in the first 19 patients [10] observed during the period from December, 2017 to January, 2019).

Table1: The courses of therapy received by the eight treated patients in the first 19 patients observed during the period from December, 2017 to January, 2019)

	Age (year)	Sex	Treatment
Patient-1 (Figure-1A)	Four	Male	Ten intramuscular injections of cerebrolysin, four ml given every third day over one months
Patient-2 (Figure-1A)	Three	Male	The first course consisted of ten intramuscular injections of cerebrolysin, one ml given every third day over one month. The second course: A-Six intramuscular injections of cerebrolysin, one ml given every five days over one month. B-Six intramuscular injections of citicoline, two ml given every five days over one month. The third course: A-Ten intramuscular injections of cerebrolysin, three ml given every three days over one month. B-Citicoline syrup, three ml orally daily as a single dose in the morning. The fourth course of therapy consisted of ten intramuscular injections of cerebrolysin, four ml given every three days over one month.
Patient-3 (Figure-1C)	Three	Male	The first course: A-Ten daily injection of cerebrolysin, one ml intramuscularly over ten days. B-Oral trifluoperazine 1mg at night. The second course: A-Ten daily injection of cerebrolysin, three ml every third intramuscularly Over one month. B-Oral trifluoperazine 1mg at night. C-Citicoline syrup, three ml orally daily as a single dose.
Patient-4	Five & half (Figure-1D)	Male	A-Ten daily injection of cerebrolysin, three ml intramuscularly over ten days. B-Oral trifluoperazine 1mg at night.
Patient-5	Eight (Figure-1E)	Male	Ten doses of 1 ml cerebrolysin by intramuscular injection every other day.

Table1 (Cont.): The courses of therapy received by the eight treated patients in the first 19 patients observed during the period from December, 2017 to January, 2019)

	Age (year)	Sex	Treatment
Patient-6	Six	Female	The first course: A-Ten daily injection of cerebrolysin, three ml every third day intramuscularly over one month. B-Oral trifluoperazine 1mg at night. C-Prochlorperazine 5mg tablet daily taken during the afternoon. The second course of: A-Ten daily injection of cerebrolysin, five ml every third day intramuscularly over one month. B-Oral trifluoperazine 1mg at night. C-Prochlorperazine, 5mg tablet daily taking during the afternoon.

Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience

			D-Risperidone 0.5 mg daily at night during the first week thereafter continued at 1 mg dose daily. The third course of treatment was the same as the third course, but with addition of Citicoline (Somazina) syrup, three ml orally daily as a single dose.
Patient-7	Six	Male	Three courses of treatment over three months and included: A-Intramuscular cerebrolysin 5ml every third day given over one month. B-Trifluoperazine in a daily dose of 5mg at night C-Prochlorperazine in a daily dose of 5mg in the afternoon was added during the third month.
Patient-8	Six	Male	Six courses of treatment over six months included: Trifluoperazine in a daily dose of 5mg at night Prochlorperazine in a daily dose of 5mg in the afternoon. Intramuscular cerebrolysin 5ml every third day given over one month.

Figure1A: Patient-1 in the first group of treated patients had moderately severe autistic features, he was looking infrequently to faces and had minimal eye contact and was poorly responding to his name. He was totally unresponsive to the doctor when asked him to take the pen and try to copy a line or just scribble. The mother also failed in making him take the pen to scribble or to draw anything

Figure1B: Patient-2 in the first group of treated patients. At the clinic, he had moderately severe autistic features, was looking infrequently to faces and had minimal eye contact, and was not responding to his name

Figure1C: The third treated patient in the first group was first seen late during April, 2018. At the clinic, he was very hyperactive and not responding to any command. He showed almost no eye contact and was not responding to his name at all. However, it was possible to convince the child by his parents with difficulty to take a pen. He was unable to copy neither a line nor a circle, but he scribbled

Figure1D: The treated fourth patient in the first group of patient. At the clinic, he was looking infrequently to faces and had no eye contact, and was not responding to his name. He was preoccupied with his toy

Figure1E: The treated fifth patient in the first group of patient had Asperger syndrome with milder autistic features. He was neither that cooperative nor responsive, and showed minimal eye contact and minimal looking at face. He took the pen but he didn't use it appropriately. However, after some directions from the mother, and some time, boy obeyed his mother and started writing and drawing. When his name was called more than one time to bring his attention and asked to look on the O clock on the wall saying "Look at this beautiful O clock on the wall", he looked at the wall. The boy was also responsive to his mother (but not to the doctor), when she asked to make a cheese to take a photo and looked at the camera

The second group of patients observed initially during the period from 18, November, 2018 to 18, July, 2019 included 51 patients.

Thirty two (17 males and 15 females) patients had autism without significant mental retardation as indicated by adequate urine and bowel control and self care skills particularly spoon feeding. They were considered to have typical autism.

Figure-2A shows a six year old boy with typical autism before treatment. He

had impaired social interaction as he was not responding appropriately to calling his name was showing no eye contact. The boy was treated for six months during which, he received 60 doses of Intramuscular cerebrolysin 5 ml every third day in the morning. He also received trifluoperazine 1mg at night and prochlorperazine 5mg during the afternoon during the early months of treatment. He also received oral citicoline 2-3 (200-300mg) ml in the morning daily few months.

Figure2A: A six year old boy with typical autism. He had impaired social interaction as he was not responding appropriately to calling his name was showing no eye contact

Figure-2B shows a seven-year old girl with typical autism before, she had impaired social interaction as she was not responding appropriately to her name was

showing no eye contact. She also showed frequent repetitive movements. Table-2 shows the courses of treatment the girl received.

Table2: The courses of treatment received by a seven year old girl (Figure-3B) who experienced complete disappearance of the autistic features

The first course of treatment started on the 18th of February 2019
Intramuscular cerebrolysin 5 ml every third day given over one month. Trifluoperazine in a daily dose of 1mg at night.
The second course of treatment started 28th of March, 2019
Intramuscular cerebrolysin 5 ml every second day. Trifluoperazine in a daily dose of 1mg at night.
The third course of treatment given during April, 2019
Intramuscular cerebrolysin 5 ml every third day. Trifluoperazine in a daily dose of 1mg at night Oral citicoline 3 ml (300mg) in the morning.
The fourth course of treatment started on the 13th of May, 2019
Intramuscular cerebrolysin 5 ml every third day. Trifluoperazine in a daily dose of 1mg at night Oral citicoline 3 ml in the morning.

Figure2B: A seven-year old girl with typical autism, she had impaired social interaction as she was not responding appropriately to her name was showing no eye contact. She also showed frequent repetitive movements

Four boys were considered to have a severe form of the disorder, one of them, the parents thought the child was deaf and consulted initially an ear specialist. One boy had prominent echolalia.

Figure-2C shows an eight-year old boy with severe autism and had significant behavioral abnormalities. He was not saying any word. At the clinic, he was unable to sit still on the chair without frequently changing the position of his body. He also

displayed marked repetitive behavior at the clinic. Figure-2D shows a three-year boy with severe autism which made his parents thought him to be deaf, but hearing assessment showed that the boy had normal hearing. At the clinic the boy was rather uncontrollable, and displayed marked repetitive movements in the form of body rocking and was trying to leave the room. The boy in figure-2D received three courses of treatment (Table-3).

Table3: Courses of treatment received by a boy in the second group who was thought to be deaf by parents (Figure-3D)

First treatment course given during February , 2019
Intramuscular cerebrolysin 5ml every third day. Trifluoperazine in a daily dose of 1mg in the morning.
Second course started on the fourth of March, 2019
Intramuscular cerebrolysin 5ml every other day. Trifluoperazine in a daily dose of 1 mg in the morning. Oral citicoline 3ml (300mg) in the morning.
Third course started on the 18th of April, 2019
Intramuscular cerebrolysin 5ml every third day, 10 doses. Prochlorperazine in a daily dose of 2.5mg at night. Oral citicoline 3ml (300mg) in the morning.

The patients in this group didn't have significant mental retardation and were classified as having rather typical autism, but most of them had developmental delay particularly in fine motor skills, and had some cognitive impairment manifested by their inability to copy forms.

Figure2C: An eight year old boy with severe autism and had significant behavioral abnormalities. He was not saying any word. At the clinic, he was unable to sit still on the chair without frequently changing the position of his body. He also displayed marked repetitive behavior at the clinic

Figure 2D: A three-year boy with severe autism which made his parents thought him to be deaf, but hearing assessment showed that the boy had normal hearing. At the clinic, before treatment, the boy was rather uncontrollable, and displayed marked repetitive movements in the form of body rocking and was trying to leave the room

However, the serious lack of communication skills per se is expected to prevent or delay the acquisition of such developmental mile stones. Figures 2E and 2F show an eight-year boy, and a six-year boy with autism who were unable to copy a circle.

In the second group of patients, thirteen patients were considered to have atypical autism or pervasive developmental disorder not otherwise specified (10 boys and 3 girls), in eleven of them, the disorder was considered atypical because of the association with significant degree of mental retardation as indicated by the lack of adequate adaptive skills particularly urine and bowel control, and lack of self-care skills especially appropriate spoon feeding.

One patient was considered to have atypical autism because of the presence of an acceptable eye contact and response appropriately to name in most instances.

Six patients (five boys, and one girl) were considered to have a severe form of the disorder. At the clinic, one of the boys with severe disorder was behaving as if he was absolutely not seeing or hearing the doctor for more than five minutes.

A five-year old girl was considered to have the mildest disorder among patients with typical and a typical autism (Figure-2G). Although she didn't have eye contact and was not responding to calling her time, she was sometime answering questions like how are you and was responding to request of the doctor with the encouragement of her parents.

One boy with severe condition was overweight (Figure-2H), and the mother thought that his sister had the same condition, but she couldn't brought her for consultation because the parents were divorced, and the girl was under the care of her father. At the clinic the boy was uncontrollably hyperactive and showed marked repetitive movements. The treatment of the boy with severe autism associated with mental retardation who was overweight (Figure-2H) is summarized in table-4. He received 10 courses of treatment over 10 months.

An other boy with atypical autism had infantile left hemiplegia and seizures, and an other boy had small ventricular defect during infancy. One boy with atypical autism developed insulin dependent diabetes mellitus.

Figure2E: An eight-year boy with autism who was unable to copy a circle

Figure2F: A six-year boy with autism who was unable to copy a circle

Figure2G: A five-year old girl with the mildest autism .She accepted the doctor request to take a pen, but she couldn't copy anything. She also had the higher vocabulary of all patients with autism of about 25-30 words, and she waved goodbye when the mother asked her to wave goodbye when leaving

Figure2H: A boy with severe autism associated with mental retardation that was overweight and his sister had the same condition At the clinic he was uncontrollably hyperactive and showed marked repetitive movements

Table4: Courses of treatment received by the boy with severe autism associated with mental retardation who was overweight (Figure-8H)

First treatment course started on the 17th of January 2019
A-Intramuscular cerebrolysin 5ml every other day, 10 doses.
B-Oral trifluoperazine in a daily dose of 5mg at night
C-Oral prochlorperazine in a daily dose of 5mg in the afternoon was added during the third month.
Second and third courses of treatment
A-Intramuscular cerebrolysin 5ml every other day, 10 doses monthly.
B-Oral trifluoperazine in a daily dose of 1 mg in the morning.
C-Oral prochlorperazine in a daily dose of 5mg in the afternoon was added during the third month.
D-Oral risperidone 1 mg at night.
The seven courses received over seven months
A-Intramuscular cerebrolysin 5ml every other day, 10 doses monthly.
B-Oral trifluoperazine in a daily dose of 1 mg in the morning.
C-Oral prochlorperazine in a daily dose of 5mg in the afternoon was added during the third month.
D-Oral risperidone 2 mg at night.
E- Oral citicoline 3ml (300mg) in the morning.

A four and half years old girl had brain arachnoid cyst on CT scan and MRI. Brain CT-scan at the age of four years showed right anterior basal temporal small arachnoid cyst (23 X 7 X 16 mm). CT-scan also showed that the cisterna pontis and C-P cisterns were prominent on both sides with low density. The CT-scan report also suggested the possibility of epidermoid cyst. Brain MRI confirmed the presence of a right anterior basal temporal (24 X 8 X 17

mm) with clean CSF. MRI also showed atrophic changes of the right temporal lobe.

Figure-2I shows the eight-year old girl with atypical autism which was considered to have the most severe disorder among the patients with typical and atypical autism. She was totally uncontrollable and irritable.

Figure2I: The eight-year old girl with atypical autism which was considered to have the most severe disorder among the patients with typical and atypical mental retardation. She was totally uncontrollable and very irritable

Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience

In the second group of patients, three patients had Asperger syndrome including two girls and one boy. A seven-year old girl with Asperger syndrome was considered to have the mildest form among all the patients (Figure-2J) in this series, with good language development, and

response to many requests with the encouragement of the mother. She also welcomed taking a photo with doctor. However, her social interaction was impaired as she was not responding appropriately to her name and was not showing acceptable eye contact.

Figure2J: A seven-year old girl was considered to have the mildest form among all patients in this series with good language development and response to many requests with the encouragement of the mother. She also welcomed taking a photo with doctor

A nine years old girl with Asperger syndrome and good language development, but she had delayed onset of speech after four years. We think that this patient represent a variant of Asperger syndrome with late onset development of language can initially misdiagnosed as a case of autism.

Her measured IQ test ranged from 85 to 110. She left school because of poor social interaction and communication and emotional fluctuation. At the clinic, she

showed alternating mood, she was smiling and almost crying with in the same minute and without obvious reason (Figure-2K). Initial treatment of this patient included:

Intramuscular cerebrolysin 5 ml daily for 10 days.

Oral trifluoperazine in a daily dose of 1 mg at night.

Oral prochlorperazine 5mg in the afternoon.

Figure2K: The girl Asperger syndrome and good language development, but she had delayed onset of speech after four years. She had prominent emotional fluctuation. At the clinic, before treatment she was showing alternating mood, smiling and almost crying with in the same minute and without obvious reason

Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience

In the second group of patients, two boys (Figures-2M and 2L) had childhood disintegrative disorder (Heller syndrome),

one of them have changes on brain MRI suggestive of cerebral vasculitis. The case of the two boys was previously reported [9].

Figure2M: A four-year old boy with Heller syndrome. He who was considered normal until shortly after the age of two and half years when the family thought that he was gradually becoming stupid with gradual deterioration of social interaction. Thereafter, he experienced loss of adaptive self care skills with loss of bowel control and the development of repetitive behaviors. At the clinic, the boy was not saying any word, but he was responding to his name and had some eye contact, but he was not communicating or responding to any question or request. He showed marked repetitive behaviors

Figure2L: A nine-year boy who was considered normal by the age of four years. The child illness started insidiously with gradual deterioration in speech and cognition, development of abnormal behaviors including motor stereotypies, loss of communication and social skills, and deterioration in adaptive self-care skills including bowel and bladder control, eating, dressing and undressing. Within several months, the boy reached a state of overtly bizarre behavior and dementia, and was saying nothing. At the clinic, the boy showed marked repetitive movements, and was rather uncontrollable and tried to move from place to place in the room

The second group of patients also included three-year girl had Rett syndrome and her case and early treatment was published [7]. She was hypotonic, ataxic, and had abnormal movements of the upper limbs. She was unable to sit alone on a chair and showed no eye contact and was not responding to her name. She didn't have purposeful hand movement and was not able to hold things. She couldn't be held erect in the standing position. She was not saying any word nor was babbling. The girl received two treatment courses. The first course included intramuscular cerebrolysin 1ml daily for ten days. The second course included 10 cerebrolysin injections, 3ml every third day, and oral citicoline.

The third group of patients was observed during the period from June, 2019 to November, 2019, it included forty-six new patients (38 males and eight females). Twenty-four patients (52%) including 20 boys and 4 girls received a diagnosis of typical autism based on the lack of obvious evidence of mental

retardation and acceptable adaptive behaviors including bowel control and good spoon feeding.

Four of the 21 patients with typical autism including three boys and one girl were considered to have classic autism (Kanner syndrome) as it was possible to demonstrate that they had good intelligence.

Two male patients in this group had significant echolalia including one of the patients with classic autism (Kanner syndrome), and one boy with classic autism (Kanner syndrome) had Occasional echolalia. One boy had significant aggressive behavior and was frequently beating his mother.

One boy had spastic cerebral palsy and was having difficulties in standing and walking (Figure-3A). A girl in this group had brain MRI which showed normal findings, and a boy with classic autism (Kanner syndrome) had brain CT-scan which also showed normal findings.

Figure3A: *One of the patients with typical autism was boy who had spastic cerebral palsy and was having difficulties in standing and walking*

In the third group of patients, seventeen patients (37%) including 14 boys and 3 girls received a diagnosis of atypical autism based on evidence of mental retardation indicated by poor and late development of adaptive behaviors

including bowel control and good spoon feeding.

In one girl, atypical autism was secondary to phenylketonuria (Figure-3B). Four patients were brothers each two of them from two unrelated families.

Figure3B: *A girl with atypical autism associated with severe mental retardation and her condition was secondary to phenylketonuria. She was very irritable and was very difficult to control at the clinic*

Significant behavioral abnormalities including biting others including sibling was observed in three boys, one of them also had gait abnormalities attributed to birth asphyxia and his CT-scan showed evidence of slight brain atrophy with mild dilatation of the ventricular system. Figure-3C shows an eight year old boy with severe atypical autism associated with significant behavioral abnormalities including biting his sister; at the clinic he displayed significant repetitive movements.

Figure-3D shows a seven-year old boy with classic autism (Kanner syndrome)

who had impaired social interaction and communication dominated by the lack of response to his name and poor eye contact. However, the mother demonstrated that he has no cognitive impairment as he write could words and solve simple math problems (Figure-3E). Table-5 shows the two courses of treatment received by the boy in figure-3D over 50 days.

Four patients including three boys and one girl (8.7%) received the diagnosis of Asperger syndrome with acceptable language development by definition.

Figure3C: *An eight year old boy with severe atypical autism associated with significant behavioral abnormalities including biting his sister; at the clinic he displayed significant repetitive movements*

Figure3D: A seven-year old boy with classic autism (Kanner syndrome). He had impaired social interaction and communication dominated by the lack of response to his name and poor eye contact.

Figure3E: A seven-year old boy with classic autism (Kanner syndrome) who had impaired social interaction and communication dominated by the lack of response to his name and poor eye contact. However, the mother demonstrated that he has no cognitive impairment as he write could words and solve simple math problems

Table5: Courses of treatment received by the boy in figure-3D

FIRST COURSE
1-Intramuscular cerebrolysin 5 ml every other day (10 doses).
2-Trifluoperazine 1mg in the morning.
3-Prochlorperazine 2.5 mg in the afternoon.
SECOND COURSE
1-Intramuscular cerebrolysin 5 ml every third day (10 doses over 30 days).
2-Trifluoperazine 1mg in the morning.
3-Prochlorperazine 5 mg in the afternoon.
4-Oral citicoline 3ml (275 mg) in the morning.

One boy was considered to have pervasive developmental disorder otherwise not specified because despite impaired social interaction and communication dominated his disorder, he lacked the typical features of poor eye contact and non-response to his name.

In the third group of patients, twenty six (66.6%) patients received neuroleptic to control significant over activity and other behavioral abnormalities; six of them required triple neuroleptics therapy (Trifluoperazine, prochlorperazine, risperidone), thirteen patients received two neuroleptics (Trifluoperazine and prochlorperazine), five patients received only trifluoperazine, prochlorperazine, and two patients received only prochlorperazine). Three patients received oral citicoline during the follow-up period with the aim of initiation or improving speech.

Results

In the first nineteen patients (observed during the period from December, 2017 to January, 2019), all the seven patients with autism and the patient with Asperger syndrome treated with the new therapeutic approach experienced improvement and marked lessening of the autistic features with six patients (Patients 1,2,3,4,6,8 [Table-1]) showed complete disappearance of the main autistic features. The fifth patient with Asperger syndrome

received a short course with relatively very small dose compared to other patients. Treatment was also associated with initiation of speech and improvement of repetitive behaviors. When these six patients were examined by physicians after treatment, the physicians couldn't identify any autistic feature and didn't make the diagnosis of an autistic disorder or autism. No patient developed any side effects. It seems that the six patients who achieved complete disappearance of the main autistic features will need an intensive learning especially of speech to abolish the effect of the time when they were under the effect of autistic behavior, and to push them toward a possible cure of their illness. Figure-4A shows the second patient after treatment. After completion of four courses of treatment [Table-1], the boy social interaction was perfectly normal with acceptable looking at face and eye contact. He was normally responding to calling his name. The boy was happy when the doctor asked him to take a photo together. The parents reported obvious improvement in his speech. Figure-4B shows patient-3 after treatment [Table-1]. The boy showed normal social interaction manifested by appropriate response to his name, normal eye contact, responding to the doctor when asked him to take the pen and tried to draw a line and a circle. He also waved goodbye when leaving the examination room.

Figure4A: shows the second patient after treatment. After completion of four courses of treatment [Table-1], the boy social interaction was perfectly normal with acceptable looking at face and eye contact. He was normally responding to calling his name.

Figure4B: Patient-3 after treatment [Table-1].The boy showed normal social interaction manifested by appropriate response to his name, normal eye contact, responding to the doctor when asked him to take the pen and tried to draw a line and a circle. He also waved goodbye when leaving the examination room.

Figure-4C shows patient-4 after treatment [Table-1]. At the clinic, the boy social interaction was perfectly normal with acceptable looking at face and eye contact. He was normally responding to calling his name, talking with doctor. His mother reported lessening of hyperactivity and improvement of his responsiveness, and speech. Figure-4D shows patient-6 after the third course of treatment [Table-1]. She started babbling and was having good eye contact, and was responding to her name. She accepted to take a pen to copy a line. She tried to copy a line, a circular figure, and then she started scribbling. She also accepted to take a photo with the doctor. Figure-4E shows patient-8 after the six months of treatment [Table-1]. He had normal social interaction with good eye

contact, and was responding to his name. He also accepted to take a photo with the doctor. The boy was able to study at private primary school as governmental schools don't accept joining primary school at his age.

Ten of eleven patients observed during the same year who didn't receive this treatment or were treated with other treatments such as omega-3 and risperidone didn't show any lessening effect in the autistic features.

A striking example of these patients was a sixteen years old boy who received before referral many therapeutic interventions and special education, but continued to have severe autistic features and was unable to say any word (Figure-5).

Figure4C: shows patient-4 after treatment [Table-1]. At the clinic, the boy social interaction was perfectly normal with acceptable looking at face and eye contact. He was normally responding to calling his name, talking with doctor

Figure4D: Patient-6 after the third course of treatment [Table-1]. She had good eye contact, and was responding to her name. She accepted to take a pen to copy a line. She tried to copy a line, a circular figure, and then she started scribbling. She also accepted to take a photo with the doctor

Figure4E: Patient-8 after the six months of treatment [Table-1]. He had normal social interaction with good eye contact, and was responding to his name. He accepted to take a photo with the doctor

Figure5: The sixteen year old boy who received before referral many therapeutic interventions and special education, but continued to have severe autistic features and was unable to say any word

In the second group of patients observed initially during the period from 18, November, 2018 to 18, July, 2019, it was not possible to document the treatment details of all patients. However, most patients experienced some improvement during follow-up including one of the boys with Heller syndrome (Figure-2M) and the girl with Rett syndrome. The boy in the second group of patients who was thought

to be deaf by the parents (Figure-2D), after three courses of treatment (Table-3), the improvement was enough to convince the parents that the child was not deaf. At the clinic, after treatment, the child was more controllable and showed much less body rocking movements (Figure-6A). Treatment was also associated with initiation of speech and improvement of repetitive behaviors in many patients.

Figure6A: *At the clinic, after treatment, the boy was more controllable and showed much less body rocking movements. The parents was convinced that he was not deaf*

The nine years old girl with Asperger syndrome (**Figure-2K**) and good language development, After 10 days of treatment, her behavior and emotional

swinging improved. She became rather passionate, and when leaving she insisted on hugging the doctor and kissing him (Figure-6B).

Figure6B: *The girl with Asperger syndrome. At the clinic, after 10 days of treatment, her behavior and emotional swinging improved*

It was possible to document complete disappearance of the main autistic features (Impaired social interaction and communication dominated by the lack of response to their name and poor eye contact) in 10 patients including the six year old boy with typical autism in Figure-3A, the seven-year old girl with typical

autism in Figure-3B, and two boys with Asperger syndrome. Figure-6C shows the six year old boy with typical autism in Figure-2A after treatment. At the clinic, the boy had normal social interaction with appropriate response to his name. He was greeting the doctor and waving goodbye when leaving the clinic.

Figure6C: *The six year old boy with typical autism in Figure-2A after treatment (Table-2). At the clinic, the boy had normal social interaction with appropriate response to his name. He was greeting the doctor and waving goodbye when leaving the clinic*

Figure-6D shows the seven-year old girl with typical autism in Figure-2B after treatment. The girl had normal social interaction and she responded to the doctor request to take a pen and copy something. She also waved goodbye when she was leaving the clinic in response to the doctor waving goodbye (Figure-6E).

Figure-6F shows the seven-year old girl with typical autism who was totally not responsive before treatment. After treatment, the girl had normal social interaction and she responded to the doctor request to take a pen and copy something. She also accepted taking a photo with doctor.

Figure-6G shows a girl with autism who joined private school after six months of treatment was her teachers reported that was the most intelligent pupil in her class. At the clinic she had normal social interaction and accepted to take a photo with the doctor.

Figure-6H shows one of the boys with Asperger syndrome after four months of treatment. At the clinic, the boy had normal social interaction with appropriate response to his name. He was greeting the doctor and waving goodbye when leaving the clinic.

Figure6D: *shows the seven-year old girl with typical autism in Figure-3B after treatment. The girl had normal social interaction and she responded to the doctor request to take a pen and copy something*

Figure6E: The seven-year old girl with typical autism in Figure-3B after treatment. She also waved goodbye when she was leaving the clinic in response to the doctor waving goodbye

Figure6F: The seven-year old girl with typical autism who was totally not responsive before treatment. After treatment, the girl had normal social interaction and she responded to the doctor request to take a pen and copy something. She also accepted taking a photo with doctor

Figure6G: A girl with autism who joined private school after six months treatment was her teachers reported that was the most intelligent pupil in her class. At the clinic she had normal social interaction and accepted to take a photo with the doctor

Figure6H: One of the boys with Asperger syndrome after four months of treatment. At the clinic, the boy had normal social interaction with appropriate response to his name. He was greeting the doctor and waving goodbye when leaving the clinic

The boy with severe autism associated with mental retardation who was overweight (Figure-2H) showed complete disappearance of the main autistic features after ten courses of treatment (Table-4). He was responding to name and had good eye contact, but he remained obviously mentally retarded having poor cognition and poor adaptive behaviors and his speech was not developed.

In the he third group of patients which was observed during the period from June, 2019 to November, 2019, all the patients experienced some improvement during follow-up. It was possible to document complete disappearance of the main autistic features

(Impaired social interaction and communication dominated by the lack of response to their name and poor eye contact) in four patients.

The first patient was a five-year old boy with typical autism, who was first seen during June, 2019. He had poor language development and impaired social interaction and communication dominated by the lack of response to his name and poor eye contact. He received three courses of intramuscular cerebrolysin over three months period. In the first course, he received cerebrolysin 3 ml every other day (10 doses). In the second course, he received cerebrolysin 5 ml every other day (10 doses). In the third course, he received

cerebrolysin 5 ml every other third (10 doses). During the three courses, he was also receiving trifluoperazine 1mg at night.

Treatment was started on 20th of June, 2019, when the boy was seen after completing the three treatment courses on the 19th of September, he didn't have the main autistic features as he responding to name, greeting and talking with doctor with good eye contact, and with obvious improvement in his speech.

The second patient was a seven-year old boy with classic autism (Kanner syndrome) who was first seen during August, 2019 (Figure-3D, treatment in table-5). He had poor language development and impaired social interaction and communication dominated by the lack of response to his name and poor eye contact. He had prominent

repetitive movements also. He had very good adaptive skills, and the mother demonstrated that he has no cognitive impairment as he write could words and solve simple math problems .

After treatment, the boy had acceptable social interaction and communication with improved speech. He was normally responding to his name and had good eye contact. He accepted the doctor request to take a pen to write something without the need for the help of mother, and he easily accepted to take photo with the doctor. He also waved goodbye in response to the doctor (Figure-7).

In addition to these two boys, another two boys, one with atypical autism and one with atypical autism also experience complete disappearance of their main autistic features.

Figure7: The second patient in the third group who experienced complete disappearance of the main autistic features: After treatment, the boy had acceptable social interaction and communication. He accepted the doctor request to take a pen to write something without the need for the help of mother, and he easily accepted to take photo with the doctor. He also waved goodbye in response to the doctor

Discussion

Impairment of social interactions is the most important distinguishing feature that makes autism and other autistic disorders distinctive from other developmental disorders. Marked

improvement or disappearance of autistic features in these disorders has not been reported with any therapy before [1, 5, 10, 11].

Cerebrolysin is a mixture of free amino acids (85%) and 15% biologically active low molecular weight amino acid

sequences which include low molecular weight neuro-peptides (Brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor [12].

Cerebrolysin has been used safely with benefit in a variety of neuropsychiatric disorders including idiopathic mental retardation [13,14,15,16], cerebral palsy [17,18,19], brain atrophy [20], myelomeningocele [21], pediatric juvenile spinal muscular atrophy [22,23], pediatric Charcot Marie Tooth disease [24,25], kernicterus [26,27,28], agenesis of corpus callosum with colpocephaly [29,30].

Citicoline (cytidine diphosphate-choline) or cytidine 5 diphosphocholine is a psycho-stimulant/nootropic. Citicoline has a very low toxicity and has been approved for treatment of head trauma, stroke, and neurodegenerative disease in Japan and Europe [31, 32].

Conclusion

In this paper, we have demonstrated the possibility of cure of autistic disorders including autism and Asperger syndrome with use of individualized courses of intramuscular cerebrolysin as the main therapy for the main autistic features (Impaired social interaction and communication dominated by the lack of response to their name and poor eye contact).

Understanding, a cure of autism will not immediately abolish the cumulative effect of the condition on learning, behavior, and speech development before cure.

Acknowledgement

1-The author would to express his gratitude for the parents of the patients who accepted publishing their photos.

2-Many figures were previously published, and the author has their copyright.

References

- [1] Al-Mosawi AJ. Pervasive developmental disorders in Iraqi Children. *Journal of Psychiatry Research Reviews & Reports* 2019; 1(1): 1-8.
- [2] Al-Mosawi AJ. The pattern of pervasive developmental disorders in Iraqi children. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-3-330-05029-7).
- [3] Al-Mosawi AJ. Pediatric psychiatry: An accredited training course. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-86510-9).
- [4] Al-Mosawi AJ. Case studies in pediatric psychiatry: An approach to deep learning. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2020 (ISBN: 978-620-2-52071-3).
- [5] Al-Mosawi AJ. A new therapeutic approach for pervasive developmental disorders. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-3-659-86602-9).
- [6] Al-Mosawi AJ. Asperger syndrome and regressive autism. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-82643-8).
- [7] Al-Mosawi AJ. New therapies for Rett syndrome. *J Bio Innov* 2019; 8(3): 301-307.
- [8] Al-Mosawi AJ. Childhood dementia: Heller syndrome. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-3-330-04944-4).
- [9] Al-Mosawi AJ. Heller syndrome in two Iraqi children. *Clinical Research and Trials* 2019; Volume 5: 1-3.
- [10] Al-Mosawi AJ. The use of cerebrolysin and citicoline in autism and Asperger syndrome. *J Bio Innov* 2019; 8(1): 99-108.
- [11] Al-Mosawi AJ. A Unique Experience with Mental and Developmental Retardation: Innovative Medical Therapies for Idiopathic Mental Retardation. *EC Clinical and Medical Case Reports* 2020; 3(5): 42-54.
- [12] Al-Mosawi AJ. Clinical uses of Cerebrolysin in Pediatric Neuropsychiatry. *Science World Journal of Pharmaceutical Sciences* 2020; 1(1): 1-4.
- [13] Al-Mosawi AJ. The etiology of mental retardation in Iraqi children. *SunKrist Journal of Neonatology and Pediatrics*. 2019; 1(1):1-9.
- [14] Al-Mosawi AJ. A novel therapeutic approach for idiopathic mental retardation. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-81808-2).
- [15] Al-Mosawi AJ. The pattern of mental retardation in Iraqi children. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-613-9-47350-2).
- [16] Al-Mosawi AJ. A Unique Experience with Mental and Developmental Retardation:

- Innovative Medical Therapies for Idiopathic Mental Retardation. EC Clinical and Medical Case Reports 2020; 3(5): 42-54.
- [17] Al-Mosawi AJ. New Therapies for the Treatment of Spastic Cerebral Palsy Med J Clin Trials Case Stud 2019; 3(2): 000209.
- [18] Al-Mosawi AJ. The pattern of cerebral palsy in Iraqi children. Med Life Clin 2019; 1(1):1001.
- [19] Al-Mosawi AJ. A novel therapeutic approach for the treatment of cerebral palsy. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2017 (ISBN: 978-620-2-07134-5).
- [20] Al-Mosawi AJ. A new therapeutic approach for the treatment of brain atrophy. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2017 (ISBN: 978-620-2-07438-4).
- [21] Al-Mosawi AJ. New medical therapies for the treatment of myelomeningocele. Surgical Medicine Open Access Journal (ISSN: 2578-0379) 2019; 2(4): 1-4.
- [22] Al-Mosawi AJ. A novel therapy for pediatric juvenile spinal muscular atrophy. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-89719-3).
- [23] Al-Mosawi AJ. The use of cerebrolysin in pediatric Wohlfart Kugelberg Welanders syndrome. MOJ Clinical & Medical Case Reports (e-ISSN: 2381-179X) 2020; 10(1):20-23. DOI: 10.15406/mojcr. 2020. 10.00335
- [24] Al-Mosawi AJ. A novel therapy for pediatric Charcot Marie Tooth disease. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-8-39043-5).
- [25] Al-Mosawi AJ. The use of Cerebrolysin in Pediatric Charcot Marie Tooth Disease. JOURNAL OF NEUROLOGICAL RESEARCH AND THERAPY (ISSN: 2470-5020) 2020; 3(2):17-21. DOI: 10.14302/issn.2470-5020.jnrt-20-3226
- [26] Al-Mosawi AJ. A novel therapeutic approach for the neurological complications of kernicterus. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2018 (ISBN: 978-613-9-98425-1).
- [27] Al-Mosawi AJ. The novel use of cerebrolysin and citicoline in the treatment of kernicterus. Online Journal of Neurology and Brain Disorders (ISSN: 2637-6628) 2019; 3 (1): 208-212. DOI: 10.32474/OJNBD.2019.03.000151
- [28] Al-Mosawi AJ. New Therapies for the Treatment of Ataxic Cerebral Palsy Caused by Kernicterus. EC Clinical and Medical Case Reports 2020; 3(4): 26-31.
- [29] Al-Mosawi AJ. Agenesis of corpus callosum with colpocephaly: A novel therapy. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019. (ISBN: 978-613-9-45076-3).
- [30] Al-Mosawi AJ. The use of piracetam and cerebrolysin in the treatment of agenesis of corpus callosum with colpocephaly. EC clinical and medical case reports 2020; 3(1): 01-05.
- [31] Al-Mosawi AJ. The Use of Citicoline in Pediatric Neurology and Pediatric Psychiatry. Austin Pediatrics (ISSN: 2381-8999) 2019; 6(1): 1071-1072.
- [32] Al-Mosawi AJ. Citicoline research progress. 1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-620-0-11372-6).

Citation: Aamir Jalal Al-Mosawi, (2020), "Cure of Autistic Disorders: Mission Impossible is Possible in an Illustrated Pioneering Experience", Arch Health Sci; 4(1): 1-26.

DOI: 10.31829/2641-7456/ahs2020-4(1)-113

Copyright: © 2020 Aamir Jalal Al-Mosawi, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.